TABLE 2.

Percentage reduction pre‐ to post‐treatment change

SNP	Ref	Alt	Gene (GenBank Reference sequence#)	CHR	BP	MAF	Mean_WT %HA days reduced	Mean_Carrier %HA days reduced	P value	Resp.
rs10779261	C	T	USH2A (NC_000001.11)	1	216,595,306	0.27	0.20	−0.01	0.00408	−
rs6443266	A	G	TTLL3 (NC_000003.12)	3	9,841,989	0.28	0.22	−0.01	0.00434	−
rs17844444	G	A	PCDHB6 (NC_000005.10)	5	140,532,165	0.18	0.17	−0.04	0.00081	−
rs3733694	A	G	PCDHB7 (NC_000005.10)	5	140,558,528	0.18	0.17	−0.03	0.00111	−
rs17096961	G	A	PCDHB7 (NC_000005.10)	5	140,559,849	0.19	0.17	−0.02	0.00340	−
rs1982151	A	G	RMI1 (NC_000009.12)	9	86,617,265	0.27	0.21	−0.03	0.00439	−
rs10882386	G	A	PLCE1 (NC_000010.11)	10	95,790,669	0.24	0.00	0.23	0.00529	+
rs1531394	T	A	ANO3 (NC_000011.10)	11	26,353,643	0.40	0.25	0.03	0.00818	−
rs116903927	A	G	KDM2A (NC_000011.10)	11	67,022,766	0.02	0.12	−0.43	0.00912	−
rs2230433	G	C	ITGAL (NC_000016.10)	16	30,518,041	0.28	0.01	0.20	0.00266	+

The table shows for each Single Nucleotide Polymorphism, the reference and base alteration, the Gene in which the alteration resides, chromosome, the base pair, the minor allele frequency, the mean decrease in headache days from pre‐treatment to post‐treatment in individuals who had no copy of the alternate allele (reference DNA base) and the mean decrease in headache days in individuals who had at least one copy of the minor allele (DNA base alteration). These values show the magnitude and direction of change in headache days from pre‐treatment to post‐treatment in the two groups. In the arithmetic model (Table 1) the value represents the number of days reduced and in the percentage model (Table 2), the percent reduction. In treatment response column, “plus” indicates verapamil treatment results in decreased headache days.